82 related articles for article (PubMed ID: 38685030)
1. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
2. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
[TBL] [Abstract][Full Text] [Related]
3. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
5. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
6. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines.
Gambardella J; Santulli G; Fiordelisi A; Cerasuolo FA; Wang X; Prevete N; Sommella E; Avvisato R; Buonaiuto A; Altobelli GG; Rinaldi L; Chiuso F; Feliciello A; Dal Piaz F; Campiglia P; Ciccarelli M; Morisco C; Sadoshima J; Iaccarino G; Sorriento D
Cell Mol Life Sci; 2023 Oct; 80(11):323. PubMed ID: 37819449
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial transplantation ameliorates doxorubicin-induced cardiac dysfunction via activating glutamine metabolism.
Sun X; Chen H; Gao R; Huang Y; Qu Y; Yang H; Wei X; Hu S; Zhang J; Wang P; Zou Y; Hu K; Ge J; Sun A
iScience; 2023 Oct; 26(10):107790. PubMed ID: 37731615
[TBL] [Abstract][Full Text] [Related]
10. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
Gradishar WJ; Moran MS; Abraham J; Abramson V; Aft R; Agnese D; Allison KH; Anderson B; Burstein HJ; Chew H; Dang C; Elias AD; Giordano SH; Goetz MP; Goldstein LJ; Hurvitz SA; Jankowitz RC; Javid SH; Krishnamurthy J; Leitch AM; Lyons J; Mortimer J; Patel SA; Pierce LJ; Rosenberger LH; Rugo HS; Schneider B; Smith ML; Soliman H; Stringer-Reasor EM; Telli ML; Wei M; Wisinski KB; Young JS; Yeung K; Dwyer MA; Kumar R
J Natl Compr Canc Netw; 2023 Jun; 21(6):594-608. PubMed ID: 37308117
[TBL] [Abstract][Full Text] [Related]
11. Effects of melatonin on cardiac metabolic reprogramming in doxorubicin-induced heart failure rats: A metabolomics study for potential therapeutic targets.
Thonusin C; Nawara W; Arinno A; Khuanjing T; Prathumsup N; Ongnok B; Chattipakorn SC; Chattipakorn N
J Pineal Res; 2023 Aug; 75(1):e12884. PubMed ID: 37177873
[TBL] [Abstract][Full Text] [Related]
12. Glycine protects against doxorubicin-induced heart toxicity in mice.
Shosha MI; El-Ablack FZ; Saad EA
Amino Acids; 2023 May; 55(5):679-693. PubMed ID: 36967438
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Oxidative Stress and Left Ventricle Markers in Patients with Chronic Heart Failure.
Mongirdienė A; Liuizė A; Karčiauskaitė D; Mazgelytė E; Liekis A; Sadauskienė I
Cells; 2023 Mar; 12(5):. PubMed ID: 36899939
[TBL] [Abstract][Full Text] [Related]
14. Blood metabolomes as non-invasive biomarkers and targets of metabolic interventions for doxorubicin and trastuzumab-induced cardiotoxicity.
Thonusin C; Nawara W; Khuanjing T; Prathumsup N; Arinno A; Ongnok B; Arunsak B; Sriwichaiin S; Chattipakorn SC; Chattipakorn N
Arch Toxicol; 2023 Feb; 97(2):603-618. PubMed ID: 36357623
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
